カテゴリ： 世界, 医療/バイオ, Market Monitor Global

組換え抗血友病グロブリンのグローバル市場展望 2023年-2029年：バイコック、アフスティラ、アルトゥヴィイオ

■ 英語タイトル：Recombinant Antihemophilic Globulin Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC14448）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC14448
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品
■ ページ数：71
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[組換え抗血友病グロブリンのグローバル市場展望 2023年-2029年：バイコック、アフスティラ、アルトゥヴィイオ]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の組換え抗血友病グロブリン市場規模と予測を収録しています。・世界の組換え抗血友病グロブリン市場：売上、2018年-2023年、2024年-2029年
・世界の組換え抗血友病グロブリン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の組換え抗血友病グロブリン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイコック」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

組換え抗血友病グロブリンのグローバル主要企業は、Shire (Baxter)、 Bayer Healthcare、 CSL、 Pfizer、 Grifols、 Biogen、 Octapharma、 Novo Nordisk、 Greencross、 Kedrion、 BPL、 Hualan Bio、 RAAS、 Baxaltaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、組換え抗血友病グロブリンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の組換え抗血友病グロブリン市場：タイプ別、2018年-2023年、2024年-2029年
世界の組換え抗血友病グロブリン市場：タイプ別市場シェア、2022年
・バイコック、アフスティラ、アルトゥヴィイオ

世界の組換え抗血友病グロブリン市場：用途別、2018年-2023年、2024年-2029年
世界の組換え抗血友病グロブリン市場：用途別市場シェア、2022年
・臨床治療、医薬品研究、その他

世界の組換え抗血友病グロブリン市場：地域・国別、2018年-2023年、2024年-2029年
世界の組換え抗血友病グロブリン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における組換え抗血友病グロブリンのグローバル売上、2018年-2023年
・主要企業における組換え抗血友病グロブリンのグローバル売上シェア、2022年
・主要企業における組換え抗血友病グロブリンのグローバル販売量、2018年-2023年
・主要企業における組換え抗血友病グロブリンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Shire (Baxter)、 Bayer Healthcare、 CSL、 Pfizer、 Grifols、 Biogen、 Octapharma、 Novo Nordisk、 Greencross、 Kedrion、 BPL、 Hualan Bio、 RAAS、 Baxalta

*************************************************************

・調査・分析レポートの概要
組換え抗血友病グロブリン市場の定義
市場セグメント
世界の組換え抗血友病グロブリン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の組換え抗血友病グロブリン市場規模
世界の組換え抗血友病グロブリン市場規模：2022年 VS 2029年
世界の組換え抗血友病グロブリン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの組換え抗血友病グロブリンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の組換え抗血友病グロブリン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：バイコック、アフスティラ、アルトゥヴィイオ
組換え抗血友病グロブリンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：臨床治療、医薬品研究、その他
組換え抗血友病グロブリンの用途別グローバル売上・予測

・地域別市場分析
地域別組換え抗血友病グロブリン市場規模 2022年と2029年
地域別組換え抗血友病グロブリン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Shire (Baxter)、 Bayer Healthcare、 CSL、 Pfizer、 Grifols、 Biogen、 Octapharma、 Novo Nordisk、 Greencross、 Kedrion、 BPL、 Hualan Bio、 RAAS、 Baxalta
...

This research report provides a comprehensive analysis of the Recombinant Antihemophilic Globulin market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Recombinant Antihemophilic Globulin market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Recombinant Antihemophilic Globulin, challenges faced by the industry, and potential opportunities for market players.
The global Recombinant Antihemophilic Globulin market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Recombinant Antihemophilic Globulin market presents opportunities for various stakeholders, including Clinical Treatment, Drug Research. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Recombinant Antihemophilic Globulin market. Additionally, the growing consumer demand present avenues for market expansion.
The global Recombinant Antihemophilic Globulin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following steps: gene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.
Key Features:
The research report on the Recombinant Antihemophilic Globulin market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Recombinant Antihemophilic Globulin market.
Market Overview: The report provides a comprehensive overview of the Recombinant Antihemophilic Globulin market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Baikoc, Afstyla), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Recombinant Antihemophilic Globulin market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Recombinant Antihemophilic Globulin market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Recombinant Antihemophilic Globulin market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Recombinant Antihemophilic Globulin market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Recombinant Antihemophilic Globulin market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Recombinant Antihemophilic Globulin market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Recombinant Antihemophilic Globulin, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Recombinant Antihemophilic Globulin market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Recombinant Antihemophilic Globulin market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Baikoc
Afstyla
Altuviiio
Market segment by Application
Clinical Treatment
Drug Research
Others
Global Recombinant Antihemophilic Globulin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Shire (Baxter)
Bayer Healthcare
CSL
Pfizer
Grifols
Biogen
Octapharma
Novo Nordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Baxalta
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Antihemophilic Globulin, market overview.
Chapter 2: Global Recombinant Antihemophilic Globulin market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Antihemophilic Globulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Antihemophilic Globulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Antihemophilic Globulin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Recombinant Antihemophilic Globulin Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Antihemophilic Globulin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Antihemophilic Globulin Overall Market Size
2.1 Global Recombinant Antihemophilic Globulin Market Size: 2022 VS 2029
2.2 Global Recombinant Antihemophilic Globulin Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Recombinant Antihemophilic Globulin Sales: 2018-2029
3 Company Landscape
3.1 Top Recombinant Antihemophilic Globulin Players in Global Market
3.2 Top Global Recombinant Antihemophilic Globulin Companies Ranked by Revenue
3.3 Global Recombinant Antihemophilic Globulin Revenue by Companies
3.4 Global Recombinant Antihemophilic Globulin Sales by Companies
3.5 Global Recombinant Antihemophilic Globulin Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Recombinant Antihemophilic Globulin Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Recombinant Antihemophilic Globulin Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Antihemophilic Globulin Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Antihemophilic Globulin Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Antihemophilic Globulin Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Antihemophilic Globulin Market Size Markets, 2022 & 2029
4.1.2 Baikoc
4.1.3 Afstyla
4.1.4 Altuviiio
4.2 By Type – Global Recombinant Antihemophilic Globulin Revenue & Forecasts
4.2.1 By Type – Global Recombinant Antihemophilic Globulin Revenue, 2018-2023
4.2.2 By Type – Global Recombinant Antihemophilic Globulin Revenue, 2024-2029
4.2.3 By Type – Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
4.3 By Type – Global Recombinant Antihemophilic Globulin Sales & Forecasts
4.3.1 By Type – Global Recombinant Antihemophilic Globulin Sales, 2018-2023
4.3.2 By Type – Global Recombinant Antihemophilic Globulin Sales, 2024-2029
4.3.3 By Type – Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
4.4 By Type – Global Recombinant Antihemophilic Globulin Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Recombinant Antihemophilic Globulin Market Size, 2022 & 2029
5.1.2 Clinical Treatment
5.1.3 Drug Research
5.1.4 Others
5.2 By Application – Global Recombinant Antihemophilic Globulin Revenue & Forecasts
5.2.1 By Application – Global Recombinant Antihemophilic Globulin Revenue, 2018-2023
5.2.2 By Application – Global Recombinant Antihemophilic Globulin Revenue, 2024-2029
5.2.3 By Application – Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
5.3 By Application – Global Recombinant Antihemophilic Globulin Sales & Forecasts
5.3.1 By Application – Global Recombinant Antihemophilic Globulin Sales, 2018-2023
5.3.2 By Application – Global Recombinant Antihemophilic Globulin Sales, 2024-2029
5.3.3 By Application – Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
5.4 By Application – Global Recombinant Antihemophilic Globulin Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Recombinant Antihemophilic Globulin Market Size, 2022 & 2029
6.2 By Region – Global Recombinant Antihemophilic Globulin Revenue & Forecasts
6.2.1 By Region – Global Recombinant Antihemophilic Globulin Revenue, 2018-2023
6.2.2 By Region – Global Recombinant Antihemophilic Globulin Revenue, 2024-2029
6.2.3 By Region – Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
6.3 By Region – Global Recombinant Antihemophilic Globulin Sales & Forecasts
6.3.1 By Region – Global Recombinant Antihemophilic Globulin Sales, 2018-2023
6.3.2 By Region – Global Recombinant Antihemophilic Globulin Sales, 2024-2029
6.3.3 By Region – Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.4.2 By Country – North America Recombinant Antihemophilic Globulin Sales, 2018-2029
6.4.3 US Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.4.4 Canada Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.4.5 Mexico Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.5.2 By Country – Europe Recombinant Antihemophilic Globulin Sales, 2018-2029
6.5.3 Germany Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.4 France Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.5 U.K. Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.6 Italy Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.7 Russia Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.8 Nordic Countries Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.9 Benelux Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.6.2 By Region – Asia Recombinant Antihemophilic Globulin Sales, 2018-2029
6.6.3 China Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.4 Japan Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.5 South Korea Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.6 Southeast Asia Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.7 India Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.7.2 By Country – South America Recombinant Antihemophilic Globulin Sales, 2018-2029
6.7.3 Brazil Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.7.4 Argentina Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Recombinant Antihemophilic Globulin Sales, 2018-2029
6.8.3 Turkey Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8.4 Israel Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8.5 Saudi Arabia Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8.6 UAE Recombinant Antihemophilic Globulin Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Shire (Baxter)
7.1.1 Shire (Baxter) Company Summary
7.1.2 Shire (Baxter) Business Overview
7.1.3 Shire (Baxter) Recombinant Antihemophilic Globulin Major Product Offerings
7.1.4 Shire (Baxter) Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.1.5 Shire (Baxter) Key News & Latest Developments
7.2 Bayer Healthcare
7.2.1 Bayer Healthcare Company Summary
7.2.2 Bayer Healthcare Business Overview
7.2.3 Bayer Healthcare Recombinant Antihemophilic Globulin Major Product Offerings
7.2.4 Bayer Healthcare Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.2.5 Bayer Healthcare Key News & Latest Developments
7.3 CSL
7.3.1 CSL Company Summary
7.3.2 CSL Business Overview
7.3.3 CSL Recombinant Antihemophilic Globulin Major Product Offerings
7.3.4 CSL Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.3.5 CSL Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Recombinant Antihemophilic Globulin Major Product Offerings
7.4.4 Pfizer Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Grifols
7.5.1 Grifols Company Summary
7.5.2 Grifols Business Overview
7.5.3 Grifols Recombinant Antihemophilic Globulin Major Product Offerings
7.5.4 Grifols Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.5.5 Grifols Key News & Latest Developments
7.6 Biogen
7.6.1 Biogen Company Summary
7.6.2 Biogen Business Overview
7.6.3 Biogen Recombinant Antihemophilic Globulin Major Product Offerings
7.6.4 Biogen Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.6.5 Biogen Key News & Latest Developments
7.7 Octapharma
7.7.1 Octapharma Company Summary
7.7.2 Octapharma Business Overview
7.7.3 Octapharma Recombinant Antihemophilic Globulin Major Product Offerings
7.7.4 Octapharma Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.7.5 Octapharma Key News & Latest Developments
7.8 Novo Nordisk
7.8.1 Novo Nordisk Company Summary
7.8.2 Novo Nordisk Business Overview
7.8.3 Novo Nordisk Recombinant Antihemophilic Globulin Major Product Offerings
7.8.4 Novo Nordisk Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.8.5 Novo Nordisk Key News & Latest Developments
7.9 Greencross
7.9.1 Greencross Company Summary
7.9.2 Greencross Business Overview
7.9.3 Greencross Recombinant Antihemophilic Globulin Major Product Offerings
7.9.4 Greencross Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.9.5 Greencross Key News & Latest Developments
7.10 Kedrion
7.10.1 Kedrion Company Summary
7.10.2 Kedrion Business Overview
7.10.3 Kedrion Recombinant Antihemophilic Globulin Major Product Offerings
7.10.4 Kedrion Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.10.5 Kedrion Key News & Latest Developments
7.11 BPL
7.11.1 BPL Company Summary
7.11.2 BPL Business Overview
7.11.3 BPL Recombinant Antihemophilic Globulin Major Product Offerings
7.11.4 BPL Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.11.5 BPL Key News & Latest Developments
7.12 Hualan Bio
7.12.1 Hualan Bio Company Summary
7.12.2 Hualan Bio Business Overview
7.12.3 Hualan Bio Recombinant Antihemophilic Globulin Major Product Offerings
7.12.4 Hualan Bio Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.12.5 Hualan Bio Key News & Latest Developments
7.13 RAAS
7.13.1 RAAS Company Summary
7.13.2 RAAS Business Overview
7.13.3 RAAS Recombinant Antihemophilic Globulin Major Product Offerings
7.13.4 RAAS Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.13.5 RAAS Key News & Latest Developments
7.14 Baxalta
7.14.1 Baxalta Company Summary
7.14.2 Baxalta Business Overview
7.14.3 Baxalta Recombinant Antihemophilic Globulin Major Product Offerings
7.14.4 Baxalta Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.14.5 Baxalta Key News & Latest Developments
8 Global Recombinant Antihemophilic Globulin Production Capacity, Analysis
8.1 Global Recombinant Antihemophilic Globulin Production Capacity, 2018-2029
8.2 Recombinant Antihemophilic Globulin Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Antihemophilic Globulin Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Antihemophilic Globulin Supply Chain Analysis
10.1 Recombinant Antihemophilic Globulin Industry Value Chain
10.2 Recombinant Antihemophilic Globulin Upstream Market
10.3 Recombinant Antihemophilic Globulin Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Antihemophilic Globulin Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Recombinant Antihemophilic Globulin in Global Market
Table 2. Top Recombinant Antihemophilic Globulin Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Recombinant Antihemophilic Globulin Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Recombinant Antihemophilic Globulin Revenue Share by Companies, 2018-2023
Table 5. Global Recombinant Antihemophilic Globulin Sales by Companies, (Units), 2018-2023
Table 6. Global Recombinant Antihemophilic Globulin Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Recombinant Antihemophilic Globulin Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Recombinant Antihemophilic Globulin Product Type
Table 9. List of Global Tier 1 Recombinant Antihemophilic Globulin Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Recombinant Antihemophilic Globulin Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Recombinant Antihemophilic Globulin Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Recombinant Antihemophilic Globulin Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Recombinant Antihemophilic Globulin Sales (Units), 2018-2023
Table 15. By Type - Global Recombinant Antihemophilic Globulin Sales (Units), 2024-2029
Table 16. By Application – Global Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Recombinant Antihemophilic Globulin Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Recombinant Antihemophilic Globulin Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Recombinant Antihemophilic Globulin Sales (Units), 2018-2023
Table 20. By Application - Global Recombinant Antihemophilic Globulin Sales (Units), 2024-2029
Table 21. By Region – Global Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Recombinant Antihemophilic Globulin Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Recombinant Antihemophilic Globulin Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Recombinant Antihemophilic Globulin Sales (Units), 2018-2023
Table 25. By Region - Global Recombinant Antihemophilic Globulin Sales (Units), 2024-2029
Table 26. By Country - North America Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Recombinant Antihemophilic Globulin Sales, (Units), 2018-2023
Table 29. By Country - North America Recombinant Antihemophilic Globulin Sales, (Units), 2024-2029
Table 30. By Country - Europe Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Recombinant Antihemophilic Globulin Sales, (Units), 2018-2023
Table 33. By Country - Europe Recombinant Antihemophilic Globulin Sales, (Units), 2024-2029
Table 34. By Region - Asia Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Recombinant Antihemophilic Globulin Sales, (Units), 2018-2023
Table 37. By Region - Asia Recombinant Antihemophilic Globulin Sales, (Units), 2024-2029
Table 38. By Country - South America Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Recombinant Antihemophilic Globulin Sales, (Units), 2018-2023
Table 41. By Country - South America Recombinant Antihemophilic Globulin Sales, (Units), 2024-2029
Table 42. By Country - Middle East & Africa Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Recombinant Antihemophilic Globulin Sales, (Units), 2018-2023
Table 45. By Country - Middle East & Africa Recombinant Antihemophilic Globulin Sales, (Units), 2024-2029
Table 46. Shire (Baxter) Company Summary
Table 47. Shire (Baxter) Recombinant Antihemophilic Globulin Product Offerings
Table 48. Shire (Baxter) Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Shire (Baxter) Key News & Latest Developments
Table 50. Bayer Healthcare Company Summary
Table 51. Bayer Healthcare Recombinant Antihemophilic Globulin Product Offerings
Table 52. Bayer Healthcare Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Bayer Healthcare Key News & Latest Developments
Table 54. CSL Company Summary
Table 55. CSL Recombinant Antihemophilic Globulin Product Offerings
Table 56. CSL Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. CSL Key News & Latest Developments
Table 58. Pfizer Company Summary
Table 59. Pfizer Recombinant Antihemophilic Globulin Product Offerings
Table 60. Pfizer Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Pfizer Key News & Latest Developments
Table 62. Grifols Company Summary
Table 63. Grifols Recombinant Antihemophilic Globulin Product Offerings
Table 64. Grifols Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Grifols Key News & Latest Developments
Table 66. Biogen Company Summary
Table 67. Biogen Recombinant Antihemophilic Globulin Product Offerings
Table 68. Biogen Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Biogen Key News & Latest Developments
Table 70. Octapharma Company Summary
Table 71. Octapharma Recombinant Antihemophilic Globulin Product Offerings
Table 72. Octapharma Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Octapharma Key News & Latest Developments
Table 74. Novo Nordisk Company Summary
Table 75. Novo Nordisk Recombinant Antihemophilic Globulin Product Offerings
Table 76. Novo Nordisk Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Novo Nordisk Key News & Latest Developments
Table 78. Greencross Company Summary
Table 79. Greencross Recombinant Antihemophilic Globulin Product Offerings
Table 80. Greencross Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Greencross Key News & Latest Developments
Table 82. Kedrion Company Summary
Table 83. Kedrion Recombinant Antihemophilic Globulin Product Offerings
Table 84. Kedrion Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Kedrion Key News & Latest Developments
Table 86. BPL Company Summary
Table 87. BPL Recombinant Antihemophilic Globulin Product Offerings
Table 88. BPL Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. BPL Key News & Latest Developments
Table 90. Hualan Bio Company Summary
Table 91. Hualan Bio Recombinant Antihemophilic Globulin Product Offerings
Table 92. Hualan Bio Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Hualan Bio Key News & Latest Developments
Table 94. RAAS Company Summary
Table 95. RAAS Recombinant Antihemophilic Globulin Product Offerings
Table 96. RAAS Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. RAAS Key News & Latest Developments
Table 98. Baxalta Company Summary
Table 99. Baxalta Recombinant Antihemophilic Globulin Product Offerings
Table 100. Baxalta Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. Baxalta Key News & Latest Developments
Table 102. Recombinant Antihemophilic Globulin Production Capacity (Units) of Key Manufacturers in Global Market, 2021-2023 (Units)
Table 103. Global Recombinant Antihemophilic Globulin Capacity Market Share of Key Manufacturers, 2021-2023
Table 104. Global Recombinant Antihemophilic Globulin Production by Region, 2018-2023 (Units)
Table 105. Global Recombinant Antihemophilic Globulin Production by Region, 2024-2029 (Units)
Table 106. Recombinant Antihemophilic Globulin Market Opportunities & Trends in Global Market
Table 107. Recombinant Antihemophilic Globulin Market Drivers in Global Market
Table 108. Recombinant Antihemophilic Globulin Market Restraints in Global Market
Table 109. Recombinant Antihemophilic Globulin Raw Materials
Table 110. Recombinant Antihemophilic Globulin Raw Materials Suppliers in Global Market
Table 111. Typical Recombinant Antihemophilic Globulin Downstream
Table 112. Recombinant Antihemophilic Globulin Downstream Clients in Global Market
Table 113. Recombinant Antihemophilic Globulin Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Recombinant Antihemophilic Globulin Segment by Type in 2022
Figure 2. Recombinant Antihemophilic Globulin Segment by Application in 2022
Figure 3. Global Recombinant Antihemophilic Globulin Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Recombinant Antihemophilic Globulin Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Recombinant Antihemophilic Globulin Revenue, 2018-2029 (US$, Mn)
Figure 7. Recombinant Antihemophilic Globulin Sales in Global Market: 2018-2029 (Units)
Figure 8. The Top 3 and 5 Players Market Share by Recombinant Antihemophilic Globulin Revenue in 2022
Figure 9. By Type - Global Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 11. By Type - Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 12. By Type - Global Recombinant Antihemophilic Globulin Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 15. By Application - Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 16. By Application - Global Recombinant Antihemophilic Globulin Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 20. By Region - Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 21. By Country - North America Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 22. By Country - North America Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 23. US Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 28. Germany Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 29. France Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 37. China Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 41. India Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 43. By Country - South America Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 44. Brazil Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
Figure 48. Turkey Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Recombinant Antihemophilic Globulin Revenue, (US$, Mn), 2018-2029
Figure 52. Global Recombinant Antihemophilic Globulin Production Capacity (Units), 2018-2029
Figure 53. The Percentage of Production Recombinant Antihemophilic Globulin by Region, 2022 VS 2029
Figure 54. Recombinant Antihemophilic Globulin Industry Value Chain
Figure 55. Marketing Channels


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 組換えカスケード試薬（rCR）＆組換えファクターCのグローバル市場展望 2023年-2029年：リコンビナントファクターC、リコンビナントカスケード試薬（rCR）
  • 組換えリムルス＆組換えファクターC試薬のグローバル市場展望 2023年-2029年：組換えリムルス試薬、組換えファクターC
  • 免疫グロブリン皮下注射のグローバル市場展望 2023年-2029年：2g、4g、10g、その他
  • ヒト破傷風用免疫グロブリンのグローバル市場展望 2023年-2029年：注射剤、フリーズドライ注射剤
  • 組換えヒトパピローマウイルス9価ワクチンのグローバル市場展望 2023年-2029年：女性、男性
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC14448 )"組換え抗血友病グロブリンのグローバル市場展望 2023年-2029年：バイコック、アフスティラ、アルトゥヴィイオ" (英文：Recombinant Antihemophilic Globulin Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。